Symposium - European Medical Journal

Continue

Symposiums

Dermatology
4 Mins
19 Dec 2019

Connecting the Dots Between Skin and Allergy

Allergies represent a significant, rising health concern. Recent figures indicate that 150 million Europeans experience chronic allergic disease…
Dermatology
6 Mins
12 Dec 2019

IL-23 Inhibition: From Pathophysiological Jungle to Clinical Clearance

The symposium “IL-23 Inhibition: From Pathophysiological Jungle to Clinical Clearance” took place during the 2019 annual European Academy of Dermatology…
Dermatology
10 Mins
12 Dec 2019

Latest Highlights from Guselkumab in Psoriasis from EADV 2019

Guselkumab was the first monoclonal antibody targeting the p19 subunit of IL-23 (IL-23p19) to be approved for the treatment of psoriasis.
Dermatology
10 Mins
12 Dec 2019

Management of Moderate-to-Severe Atopic Dermatitis in the Era of Targeted Treatments

Prof Augustin opened the symposium by underlining how the management of patients with moderate-to-severe atopic dermatitis (AD) has become more dynamic…
Neurology
11 Mins
12 Dec 2019

Improving Intravenous Immunoglobulin Dosing in Autoimmune Neuropathies

This symposium took place on Monday 24th June 2019, as part of the 2019 Peripheral Nerve Society (PNS) Annual Meeting in Genoa, Italy.
Hematology
3 Mins
12 Dec 2019

Anticipate Your Next Move in Chronic Myeloid Leukaemia Patient Management

Treatment decisions in chronic myeloid leukaemia (CML) are complex and require the evaluation of many factors at each stage of therapy…
Respiratory
6 Mins
12 Dec 2019

Integrating Selective Targeted Monoclonal Antibody Therapies for Improved Outcomes in Uncontrolled Asthma

Atypical production of several Th2 cytokines, including IL-4, IL-5, and IL-13, play a central pathogenic role in multiple atopic conditions.
Gastroenterology
4 Mins
5 Dec 2019

‘Old but Gold’ – Insights About Anti-TNF-α Therapy in the Treatment of Inflammatory Bowel Disease

Prof Panaccione believed that biologic therapies are generally underutilised in patients with IBD; they are started too late and prescribed to too few…